Abstract
Efficient transdisciplinary cooperation promotes the rapid discovery and clinical application of new technologies, especially in the competitive sector of oncology. In this review, written from a clinical-scientist point of view, we used glioblastoma—the most common and most aggressive primary brain tumor as a model disease with a largely unmet clinical need, despite decades of intensive research—to promote transdisciplinary medicine. Glioblastoma stem-like cells (GSCs), a special tumoral cell population analogue to healthy stem cells, are considered largely responsible for the progression of the disease and the mediation of therapy resistance. The presented work followed the concept of translational science, which generates the theoretical backbones of translational research projects, and aimed to close the preclinical gap between basic research and clinical application. Thus, this generated an integrated translational precision medicine pipeline model based on recent theoretical and experimental publications, which supports the accelerated discovery and development of new paths in the treatment of GSCs. The work may be of interest to the general field of precision medicine beyond the field of neuro-oncology such as in Cancer Neuroscience.
Highlights
Introduction and OverviewThe preclinical research gap generated between basic research mostly focused on scientific discoveries, and clinical work mostly focused on medical practice
A good example of this integration in an oncological context is the merge of the Translational Research Working Group and the Personalised Medicine Task Force of the European Society for Medical Oncology (ESMO) into a single research group in 2014 [6]
Despite the importance of preclinical research, no explicit preclinical pipelines of integrated translational precision medicine focused on neuro-oncology or glioblastoma have been described in the literature to the best of our knowledge
Summary
The preclinical research gap generated between basic research mostly focused on scientific discoveries, and clinical work mostly focused on medical practice. The complex field of glioblastoma has evidenced highly hierarchical behavior, and the most aggressive cells share equivalent characteristics and molecular markers with normal stem cells These tumor cells with stem-like traits are referred to as glioblastoma stem-like cells (GSCs) and show a direct correlation between tumor aggressiveness and their degree of stemness or differentiation. Despite the importance of preclinical research, no explicit preclinical pipelines of integrated translational precision medicine focused on neuro-oncology or glioblastoma have been described in the literature to the best of our knowledge We designed this straight-forward pipeline based on the combination of recent literature with the published experimental results of a doctoral project from our laboratory in the context of GSCs, keeping in mind a translational, patient-oriented mindset to bridge the preclinical gap, accelerate the development of next-generation therapies for neurooncology and glioblastoma, and encourage clinicians and scientist to conduct translational preclinical research
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
